Genomics & Genetics Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Genomics & Genetics Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Cystic Fibrosis
Researchers from McMaster University discuss findings in cystic fibrosis
December 12th, 2008
"Patients with cystic fibrosis (CF) are at risk for early bone loss, and demonstrate increased risks for vertebral fractures and kyphosis. A multicenter, randomized, controlled trial was conducted to assess the efficacy, tolerability, and safety of therapy with oral alendronate (FOSAMAX; Mcrck: Whitehouse Station, NJ) in adults with CF and low bone mass," scientists in Hamilton, Canada report. "Participants received placebo or alendronate, 70 mg once weekly, for 12 months. All participants received 800 IU of vitamin D and 1,000 mg of calcium daily. Adults with confirmed CF with a bone mineral density (BMD) T score of <- 1.0 were eligible for inclusion. Participants...
Source: Genomics & Genetics Weekly (2008-12-12)
|
